Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02621398 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
A Phase 1 study of Stage IIIB Non-small Cell Lung Cancer and Stage IIIA Non-Small Cell Lung Cancer, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 3
- Study locations
NCT02621398 is a Phase 1 study of Stage IIIB Non-small Cell Lung Cancer and Stage IIIA Non-Small Cell Lung Cancer that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 23 participants, below the 47-participant average among 16 other Stage IIIB Non-small Cell Lung Cancer trials with a reported enrollment target (51% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02621398, a Phase 1 study of Stage IIIB Non-small Cell Lung Cancer and Stage IIIA Non-Small Cell Lung Cancer, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase I trial studies the side effects, best dose, and best way to give pembrolizumab when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving pembrolizumab together with paclitaxel, carboplatin, and radiation therapy may kill more tumor cells.
Conditions Studied
Interventions
- DRUG Carboplatin
- OTHER Laboratory Biomarker Analysis
- DRUG Paclitaxel
- RADIATION Intensity-Modulated Radiation Therapy
- RADIATION 3-Dimensional Conformal Radiation Therapy
Study Locations (3)
Connecticut
- Yale Cancer Center - New Haven
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Pennsylvania
- University of Pennsylvania/Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-08-04 |
| Est. Completion | 2024-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02621398
The ClinicalTrials.gov registry entry for NCT02621398 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47-participant average among 16 other Stage IIIB Non-small Cell Lung Cancer trials with a reported enrollment target (51% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage IIIB Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT02621398 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, New Jersey, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02621398 about?
NCT02621398 is a clinical study titled "Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer". This phase I trial studies the side effects, best dose, and best way to give pembrolizumab when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ...
What is the current status of trial NCT02621398?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-08-04. Estimated completion is 2024-02-29.
What conditions does trial NCT02621398 study?
This clinical trial studies the following conditions: Stage IIIB Non-small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02621398?
The interventions under investigation include: Carboplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Paclitaxel (DRUG), Intensity-Modulated Radiation Therapy (RADIATION), 3-Dimensional Conformal Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02621398?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02621398 being conducted?
This trial has 3 study locations across Connecticut, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIIB Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
COMPLETED · Phase 1
-
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 1
-
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
COMPLETED · Phase 1
-
Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
COMPLETED · Phase 1
-
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
ACTIVE NOT RECRUITING · NA
-
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Stage IIIB Non-small Cell Lung Cancer
All registered trials for this condition
Stage IIIA Non-Small Cell Lung Cancer
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.